Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor–Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial

IMPORTANCE: Everolimus plus exemestane and capecitabine are approved second-line therapies for advanced breast cancer. OBJECTIVE: A postapproval commitment to health authorities to estimate the clinical benefit of everolimus plus exemestane vs everolimus or capecitabine monotherapy for estrogen rece...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Main Authors: Jerusalem, Guy, de Boer, Richard H., Hurvitz, Sara, Yardley, Denise A., Kovalenko, Elena, Ejlertsen, Bent, Blau, Sibel, Özgüroğlu, Mustafa, Landherr, László, Ewertz, Marianne, Taran, Tetiana, Fan, Jenna, Noel-Baron, Florence, Louveau, Anne-Laure, Burris, Howard
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2018
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6233772/
https://ncbi.nlm.nih.gov/pubmed/29862411
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.2262
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados